Adaptation in the form of optimal folate-related gene epistasis and skin pigmentation would be selected to maintain provision of folate coenzymes for crucial methylation and DNA-thymidylate biosynthetic processes
PHYTOCHROME-INTERACTING FACTOR 4/HEMERA-mediated thermosensory growth requires the Mediator subunit MED14
192 The TAD domain interacts with transcriptional co-activators such as p300 and CBP to promote the transcription of downstream genes
Benefits Achieve smooth, radiant skin Delivers moisture to relieve dryness Hypoallergenic toner suitable for sensitive skin Non-sticky, moisturizing milky texture Key Ingredients 86% Galactomyces Ferment Filtrate - High Moisture/Long-lasting Hydration Effect, Skin Texture Improvement Effect,Skin Elasticity Effect, Skin Brightening Effect 10 ppm Glutathione - Restores the skin's natural radiance and vitality, brightening dull and sensitive skin
The key regulatory milestones: FDA Breakthrough Therapy designation for MASH (September 2024) EMA PRIME designation for MASH (November 2023) China NMPA Breakthrough designation (June 2024) Phase 3 trials (SYNCHRONIZE-1 and SYNCHRONIZE-2) fully enrolled, results expected H1 of this year Estimated FDA filing: Late this year at the earliest Estimated FDA approval: Possibly next year, depending on Phase 3 results If Phase 3 results confirm Phase 2 findings, survodutide could reach the market within the next 12-24 months
